Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Risk of Severe Coronavirus Disease 2019 Infection in Kidney Transplant Recipients

Pilar Galindo Sacristán*, Elena Clavero García, Elisa Berta Pereira Pérez, Almudena Pérez Marfil, María José Torres Sánchez, José Manuel Osorio Moratalla, Carmen De Gracia Guindo, María Carmen Ruiz Fuentes, and Antonio Osuna Ortega

Department of Nephrology, Virgen de las Nieves University Hospital, Granada, Spain

ABSTRACT

Background. Despite all efforts, the incidence of severe coronavirus disease 2019 (COVID-19) infection has been high in renal transplant recipients, as in other groups (eg, older adults, patients with comorbidities or immunosuppression). The detection of any possible predictor of gravity could improve the early approach in these patients.

Patients and methods. We registered data from renal transplant recipients with severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection in our area for a year (March 2020 to March 2021). We collected demographics, comorbidity, body mass index, lymphocyte count, and vitamin D levels before the diagnosis. We performed statistical analysis using SPSS Statistics version 20 (IBM Corp, Armonk, NY, United States).

Results. Of 63 patients, 57.1% required hospital admission and 14.3% required intensive care. The incidence of acute renal failure was 28.6%; 34.9% developed hyperinflammatory syndrome; 67% had lymphopenia, which was severe in 13.1%; and 11 patients died. There was significant correlation between lymphocyte count before and during the infection. For hospitalization, we found differences in age, pulmonary disease, and renal function. Related factors for admission to an intensive care unit were obesity, severe lymphopenia, altered renal function, and low level of vitamin D. Predictors for mortality were age, renal function, and minimum lymphocyte count.

Conclusion. In kidney transplant recipients with COVID-19 infection, renal function determines hospitalization, and body mass index determines admission to an intensive care unit. Previous vitamin D levels are also significantly lower in patients requiring intensive care. The analysis of lymphocyte count previous to infection is correlated with the minimum level during the disease, which is a predictor of mortality, and could be a prognosis factor.

For over a year, severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) has afflicted millions of people all over the world. Despite the combined effort to prevent its spread in our community, many patients with kidney chronic disease have experienced coronavirus disease 2019 (COVID-19) infection. Thanks to the early intervention of medical societies in recording cases, we have been able to obtain precise and useful epidemiologic data [1]. As expected, hospitalization and mortality rates have been higher among transplant recipients [2,3]. However, the evolution of disease has been variable and, in some cases, similar to the general population [4].

Research groups have worked to identify potential predictors of severity, to improve early management, and to reduce complications as much as possible [5,6]. In our population, kidney disease and other comorbidities are common. All of them are associated with an increased risk of severe infection; they imply biological aging, and the majority are not modifiable [7]. Adjustments to the immunosuppressive regimen is often used in many infections of different etiologies, and we have also applied it to COVID-19 [8], although the optimal approach is not defined.

*Address correspondence to Pilar Galindo Sacristán, Department of Nephrology, Virgen de las Nieves University Hospital, 2 Fuerzas Armadas Ave, Granada, Spain 18014. Tel: +34 958020000, +34626648738. E-mail: pgalindosacristan@gmail.com

0041-1345/20
https://doi.org/10.1016/j.transproceed.2021.08.060

© 2021 Published by Elsevier Inc.

Transplantation Proceedings, 54, 18–21 (2022)
Several clinical and analytical risk parameters that involve worse prognoses (eg, hypoxemia, inflammatory syndrome, lymphopenia) had been identified before and throughout the evolution of the disease [9,10].

We carried out an observational study with kidney transplant recipients diagnosed with SARS-COV-2 to identify its course and complications and to find predictor factors previous to and during the disease.

PATIENTS AND METHODS

We created a register (from March 2020 to March 2021) of COVID cases among our renal transplant recipients. We collected data such as demographics, diabetes, cardiac or pulmonary disease, and body mass index (BMI). We also considered if there was nosocomial or community contact, the initial and late symptoms, the need of hospitalization, admission in an intensive care unit (ICU), and orotracheal intubation.

Regarding the analytical parameters, we registered data about hyperinflammatory syndrome, renal function (creatinine and estimated glomerular filtration rate by Modiﬁcation of Diet in Renal Disease), total lymphocytes (average of the last 3 analyses previous to the infection), proteinuria and vitamin D, all of them before and during COVID-19 infection. More than a half (50.8%) had blood type A, and 41.2% had blood type B. The immunosuppressive therapy included tacrolimus in 82.5% of the patients. The infection was nosocomial in 28.6% of the cases. Mortality rate was 17.5% (11 patients) (Table 1).

In 2 outpatients with mild symptoms, no laboratory follow-up information was available. Of the remaining patients, 67% had mild lymphopenia, which was severe in 13.1% of patients, and 34.4% of the patients met the criteria for hyperinflammatory syndrome. The rate of acute renal failure was 28.6%, with worsening of proteinuria in 13.1%.

All patients were under low-dose corticoid therapy, and 53.9% received a higher dose during COVID-19 occurrence (oral or intravenous). Mycophenolate was reduced or suspended in 46% of the cases.

We found significant correlation between previous lymphocytes and minimum lymphocyte count and 34.4% of the patients met the criteria for hyperinflammatory syndrome. The rate of acute renal failure was 28.6%, with worsening of proteinuria in 13.1%.

We found significant correlation between previous lymphocytes and minimum lymphocyte count during the infection ($r = 0.568; P = .000$). It was also inversely correlated with BMI ($r = −0.307; P = .016$) (Table 2).

In the univariate analysis for hospital admission (Table 3), we found significant differences regarding pulmonary disease, age, and renal function. Those who were older, had previous pulmonary pathology or had worse renal function, required hospital admission more frequently.

Concerning ICU admission, BMI was higher, renal function was worse, vitamin D level and minimum lymphocyte count

| Table 1. Baseline Characteristics and Variables During Infection |
|---------------------------------------------------------------|
| Variables Before Infection | Average ± SD (Interval)/Percentage/n | Variables During Infection | Percentage/n |
| Age (y) | 54.5 ± 12.9 (20-87) | Nosocomial contact | 28.6%/18 |
| Months with RRT | 158 ± 125 (13-516) | Hospitalization | 57.1%/36 |
| Months until transplant | 112 ± 107 (1-369) | Days of hospital stay | 18.8 ±15 |
| BMI (kg/m²) | 27.7 ± 4.7 (18-40) | Intensive care | 14.3%/9 |
| Creatinine (mg/dL) | 1.51 ± 0.6 (0.6-3.6) | Otrachral intubation | 9.5%/6 |
| Glomerular filtrate (cc/min) | 53 ± 20 (17-100) | Hyperinflammatory syndrome | 34.9% (n = 21/61) |
| Lymphocytes (U/μL) | 1857 ± 970 (336-5190) | Lymphopenia | 67.2% (n = 41/61) |
| Vitamin D (ng/mL) | 20.43 ± 8.1 (3.7-40) | Severe lymphopenia | 13.1%/8 |
| Gender | Male 57.1%/36 | Minimum lymphocyte count | 874 ± 912 (40-4890) |
| Diabetes | 20.6%/13 | AKI | 28.6%/18 |
| Pulmonary disease | 28.6%/18 | Increased proteinuria | 13.1%/8 |
| Cardiac pathology | 28.6%/18 | Corticoids | 53.9%/34 |
| Hypertension | 82.5%/52 | Immunosuppression reduction | 46%/29 |
| Blood type A-0-B | 50.8%/32−41.2%/26−7.9%/5 | Death | 17.5%/11 |

AKI, acute renal injury; BMI, body mass index; RRT, renal replacement therapy; SD, standard deviation

| Table 2. Correlations |
|-----------------------|
| Correlations | P | R of Pearson |
| Previous lymphocytes and GFR | .07 | 0.337 |
| Previous lymphocytes and minimum lymphocyte count | .000 | 0.568 |
| GFR and days of hospitalization | .016 | −0.405 |
| Vitamin D and days of hospitalization | .013 | −0.429 |
| BMI and minimum lymphocyte count | .016 | −0.307 |

BMI, body mass index; GFR, glomerular filtration rate
Admission
Mortality
Age:
ICU
nary injury. Obesity has been associated with a chronic in rates of hospitalization and mortality because of acute pulmo-

count turned out to be predictors of mortality.

Table 4. Multivariate Analysis

| Variables                  |        |        |
|----------------------------|--------|--------|
| Hospitalization            |        |        |
| Glomerular filtration      | .029   | .886   |
| Body mass index            | .04    | 1.593  |
| Previous lymphocyte count  | .045   | .998   |
| Minimum lymphocyte count   | .026   | 1.149  |
| Age                       | .008   | .991   |

BMI, body mass index; GFR, glomerular filtration rate; ICU, intensive care unit.

were lower in patients admitted to the ICU than non-ICU hospital-
ized patients.

Results for mortality showed significant differences in the fol-
lowing variables: age, renal function, minimum lymphocyte
count, and nosocomial contact. For the regression analysis
(Table 4), glomerular filtration rate was a predictor of hospitali-
zation (P = .029, Exp[B] 0.886) and BMI of ICU admission
(P = .004, Exp[B] 1.593). Previous lymphocytes were predic-
tors of severe lymphopenia (P = .045, Exp[B] 0.998). Only the age
(P = .026, Exp[B] 1.149) and the minimum lymphocyte count
turned out to be predictors of mortality.

DISCUSSION
Previous factors to diagnosis

Several studies of potential predictors of gravity in COVID-19 infec-
tion showed consistent results for older adults and comor-
bidity [5] (especially pulmonary disease, obesity, and immuno-
suppression). Among our patients, 28.6% had some type of pulmo-
nary disease, the majority of which were obstructive (COPD and OSAS). These groups have significantly higher rates of hospitalization and mortality because of acute pulmo-
nary injury. Obesity has been associated with a chronic inflam-
atory condition and altered immune regulation [11], which favors infections. Kidney transplant recipients have a higher prevalence of being overweight; the median BMI in our study was higher in those with severe hyperinflamatory syndrome and in those requiring intensive care.

The presence of decreased renal function is also common among transplant recipients. Uremia causes lower immunologic response as it has been proved after vaccination, so the infection and tumor rates are higher [12]. Renal function is also expected to be a risk factor in COVID-19 infection [5]. We found GFR as a predictor of hospitalization in our population.

Moreover, vitamin D levels before the infection were signifi-
cantly lower in patients requiring ICU admission and is associ-
ated with worse prognoses.

Lymphocyte count is usually related with infection and death from many causes [6]. Lymphopenia is considered an immuno-
hematologic biomarker [13] that reflects a premature aging with less production of “naive” lymphocytes in the thymus and increased number of memory cells. This occurs frequently in uremic syndrome and is also present before transplantation, increasing the risk of infections predominantly produced by viruses. Furthermore, it does not seems that transplantation can revert this situation [13–15]. In COVID infection, lymphopenia has showed a prognostic value before [16] and during the disease [8–10]. The average previous lymphocyte count in our study was related to the minimum level during the infection and was a predictor of severe lymphopenia.

Factors during COVID-19 disease

At the time of diagnosis, symptoms are different from one patient to another. Dyspnea and fever were found to be the main manifestations in hospitalized patients. Although we did not collect data from imaging tests, both symptoms are related to established pneumonia. Among the analytical parameters, hyperinflammatory syndrome was more frequent in patients with obesity, lower GFR, and lower vitamin D levels. These results were associated with severe lymphopenia.

Renal injury (either acute kidney injury or superimposed acute renal injury or chronic kidney disease) and increased pro-
teinuria appeared in 28.6% and 13.1% of patients, respectively, and occurred more frequently in patients with low vitamin D levels. Several pathologic mechanisms have been proposed (eg, direct cell injury or cytokine storm with consequent podocyte and tubular damage). Some cases of collapsing nephropathy have also been described [17].

Lymphopenia clearly seems a marker for poor prognosis, as was shown in several studies, and has become a predictor of mortality. We also found minimum lymphocyte count to be a useful factor.
All patients were receiving low-dose steroids, and more than half increased it. This change in treatment took place in different stages in each patient, some of them promptly and possibly coinciding with the viremic phase (which would have stimulated viral replication and lymphopenia). Nevertheless, in the majority of cases, high-dose steroids were used in the inflammatory phase of the disease. Some protocols included other drugs such as ritonavir, hydroxychloroquine, and remdesivir. Analyses of these drugs were not part of the aim of this study. Since the pandemic started, there was a general consensus in decreasing or avoiding antimebolite treatment, as is done for the management of other opportunistic infections (eg, poliomyelitis, cytomegalovirus). In our series, mycophenolate was modified in 46% of patients. However, a study [4] did not find differences between the intensity of immunosuppression and mortality. This possibly reflects the higher influence of immunologic baseline conditions related to age, uremia, and possible previous use of antithymocyte globulin, which produces a premature immunosenescence [18]. This could be the reason why previous lymphocyte count determines the evolution of COVID-19 disease. In any case, it is evident that mycophenolate, which promotes lymphopenia (overall in association with tacrolimus [19] more than cyclosporine), should be stopped or at least reduced.

In conclusion, previous markers of bad prognoses, as appears to be the case with obesity, hypovitaminosis D, and lymphopenia, could help to identify those patients who need additional medical care. Thus, the accuracy with which hospitalization and treatment are considered could be improved. We could regulate immunosuppression in a more individualized way, including immunomodulatory drugs [20,21] like lymphocyte-stimulating agents, as long as we do not find effective antivirals.

CONCLUSIONS

In kidney transplant recipients with COVID-19 infection, renal function seems to determine hospital admission, and BMI determines the admission in an ICU. Previous vitamin D levels are significantly lower in patients who required intensive care. The analysis of lymphocyte count previous to infection is correlated with the minimum level during the disease, which is a predictor of mortality, and that could be a prognostic factor.

REFERENCES

[1] Register of the Spanish Society of Nephrology- Report n 22 (18th March 2020 – 3rd April 2021) https://mailchi.mp/senerro/registro-epidemiologico-vhc-vbh-vih-1315130. [accessed 16.04.20].
[2] Azzi Y, Bartash R, Scalea J, Loarte-Campos P, Akalin E. COVID-19 and solid organ transplantation: a review article. Transplantation 2021;105:57–55.
[3] Cravedi P, Mothi SS, Azzi Y, Haverly M, Farouk SS, Pérez-Sáez MJ, et al. COVID-19 and kidney transplantation: results from the TANGO International Transplant Consortium. Am J Transplant 2020;20:3140–8.
[4] Kates OS, Haydel BM, Florman SS, Rana MM, Chaudhry ZS, Ramesh MS, et al. Covid-19 in solid organ transplant: a multicenter cohort study [e-pub ahead of print]. Clin Infect Dis 2021 accessed November 22. doi: 10.1093/cid/ciaa1097.
[5] Figliozzi S, Masi P, Ahmadz N, Tondi L, Kouti E, Aimo A, et al. Predictors of adverse prognosis in COVID-19: A systematic review and meta-analysis. Eur J Clin Invest 2020;50:e13362.
[6] Warny M, Helby J, Nordestgaard BG, Birgens H, Bojensen SE. Incidental lymphopenia and mortality: a prospective cohort study. CMAJ 2020;192:e28–33.
[7] Caillard S, Chavarot N, Francois H, Maignon M, Greze C, Kamar N, et al. Is COVID-19 infection more severe in kidney transplant recipients? Am J Transplant 2021;21:1295–303.
[8] Moris D, Kesseli S, Barbas AS. Kidney transplant recipients infected by COVID-19: review of the initial published experience. Transpl Infect Dis 2020;22:e13426.
[9] Guo YD, Ding M, Dong X, Zhang JH, Azkur AK, Azkur D, et al. Risk factors for severe and critically ill COVID-19 patients. a review. Allergy 2021;76:428–55.
[10] Kaur S, Bansal R, Kollinmutthuallin S, Gowda AM, Singh B, Mehta D, et al. The looming storm: blood and cytokines in COVID-19. Blood Rev 2021;46:100743.
[11] Korakas E, Ikonomidou I, Kousathanis F, Balampanis K, Kountouris A, Raptis A, et al. Obesity and COVID-19: immune and metabolic derangement as a possible link to adverse clinical outcomes. Am J Physiol Endocrinol Metab 2020;319:E105–9.
[12] Betjes MGH. Uremia-associated ageing of the thymus and adaptive immune responses. Toxins (Basel) 2020;12:224.
[13] Zidar DA, Al-Kindi SG, Liu Y, Krieger NI, Perzynski AT, Osnard M, et al. Association of lymphopenia with risk of mortality among adults in the US general population. JAMA Netw Open 2019;2:e1916526.
[14] Ph Attias, Melica G, Bouthoul D, De Castro N, Audard V, Stehle T, et al. Epidemiology, risk factors, and outcomes of opportunistic infections after kidney allograft transplantation in the era of modern immunosuppression: a monocentric cohort study. J Clin Med 2019;8:594.
[15] Crepin T, Carron C, Roubiou C, Gaugler B, Gaiffe E, Simula-Faivre D, et al. ATG-induced accelerated immune senescence: clinical implications in renal transplant recipients. Am J Transplant 2015;15:1028–38.
[16] Bossini N, Alberici F, Delbarba E, Valerio F, Maneti C, Posenti S, et al. Kidney transplant recipients with SARS-CoV-2 infection: The Brescia Renal Covid task force experience. Am J Transplant 2020;20:3019–29.
[17] Shetty AA, Tawhari I, Safar-Boueri L, Seif N, Alamahdi A, Gargiulo R, et al. COVID-19-associated glomerular disease. J Am Soc Nephrol 2021;32:33–40.
[18] Bamoulid J, Staek O, Crépin T, Halleck F, Saas P, Brakemeier S, et al. Anti-thymocyte globulins in kidney transplantation: focus on current indications and long-term immunological side effect. Nephrol Dial Transplant 2017:32:1601–8.
[19] Meany CJ, Sudchada P, Consiglio JD, Wilding GE, Cooper LM, Venuto RC, et al. Influence of calcineurin inhibitor and sex on mycophenolic acid pharmacokinetics and adverse effects post renal transplantation. J Clin Pharmacol 2019;59:1351–65.
[20] Fernández-Ruiz M, Aguado JM. Immunomodulatory therapies for COVID-19 in solid organ transplant recipients. Curr Transplant Rep 2023;1:11.
[21] Latere PF, François B, Colienne C, Hantson P, Jeannt R, Remy KE, et al. Association of Interleukin 7 Immunotherapy with Lymphocyte Count among patients with severe Coronavirus Disease 2019 (COVID-19). JAMA Netw Open 2020;3:e2016485.